- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Clarivate Analytics Drugs to Watch Report
Clarivate Analytics, a global insights and analytics company, announced the launch of its annual “Cortellis Drugs to Watch” report using data and analytics from Cortellis, the company’s suite of life science intelligence solutions. The report highlights seven new drugs forecasted to sell at blockbuster status ($1billion or higher) by 2023.
The drugs include Upadacitinib (AbbVie – US), which treats rheumatoid arthritis; Zolgensma (AveXis – US), which treats spinal muscular atrophy; Roxadustat (AstraZeneca – UK, FibroGen – US, Astellas – Japan), which treats anemia in chronic kidney disease patients on dialysis; Ultomiris (Alexion – US), which treats paroxysmal nocturnal hemoglobinuria; Skyrizi (Boehringer Ingelheim – DE, AbbVie – US), which treats psoriasis; AR-101 (Aimmune Therapeutics – US), which treats peanut allergies; and LentiGlobin (bluebird bio – US), which treats beta-thalassemia in transfusion-dependent patients.
For more information about each drug, how much is forecasted in sales for 2023, and to download the full report, visit here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
